



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ELSEVIER

Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid

World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic[☆]

Editorial

The World Health Organization (WHO) and STOP TB Partnership theme for World TB Day 24th March, 2022 is “Invest to End TB. Save Lives” (WHO, 2022a). Global political and scientific attention continues to be focussed on the Coronavirus disease (COVID-19) pandemic. There have been over 416 million cases of COVID-19 including 5.8 million deaths reported to the World Health Organization (WHO) as of 18th February, 2022 (WHO, 2022b). In the wake of the COVID-19 pandemic, disruption of TB services have led to an increase in the number of TB cases and TB related deaths worldwide affecting the lives and livelihoods of millions of people worldwide. The COVID-19 pandemic has reversed a decade of progress made to control the TB pandemic. (Wu et al., 2020; Alene et al., 2020; Zimmer et al., 2022; Pai et al., 2022; John Hopkins Report, 2022). World TB Day presents an opportunity to highlight that TB is the second most important cause of death from an infectious disease worldwide, and it requires equal attention as COVID-19, if not more.

For the first time since 2012, TB death rates have started to increase globally (WHO, 2021a), and the world is running out of time to deliver the UN General Assembly High Level Meeting on TB commitments made in 2018 (UNGA, 2018), where all TB stakeholders had called for:

- Acceleration of the End TB Response to reach the targets set in the political declaration of the UN High-Level Meeting on TB (UNGA, 2018).
- 40 million people with TB to be diagnosed and treated by 2022 which includes 3.5 million children and 1.5 million people with drug-resistant TB. This is in line with WHO's overall drive towards Universal Health Coverage and the joint WHO, Global Funds and Stop TB Partnership flagship initiative “Find. Treat. All. #EndTB”.
- 30 million people to be reached and initiated on TB preventive treatment by 2022, especially those people most at risk, including 24 million household contacts of TB patients (4 million of whom are children under 5, and 6 million are people living with HIV).
- Generating 15 billion USD a year to support efforts to end TB, support TB research for better science, better tools and better delivery.

These objectives for 2022 have not been achieved and there is currently an urgent need to ramp up investments in TB health services globally in the context of the COVID-19 pandemic, and ensure equitable access to diagnosing all TB cases and prevent TB deaths (UNGA, 2018; Zumla et al., 2021; Sahu et al., 2021; Chakaya et al., 2022). To advance the theme for this year's World TB Day, “Invest to end TB - save lives”, we need to keep in mind the poor global economic situation, and reflect on other innovative ways to revamp and reshape global TB control programs to achieve their maximum potential in light of the impacts COVID-19 has had on health services, especially in high TB burden countries. A recent study (Haldane et al., 2021a) assessed countries with low or high COVID-19 mortality rates and derived important implications for improving public health services and current efforts to control killer infectious diseases such as tuberculosis, malaria, HIV, measles among others. The study identified four broad pillars of a high performing response: “Partner, Coordinate, Develop and Strengthen” and four pillars which define a low performing response: “Devalue, Denial, Delays and Distrust”. The strengths of high performing countries with lower mortality rates were associated with effective partnerships and coordination on multiple levels of the response, with governments engaging with communities and purchasing partnerships to secure resources and focused on development, including increasing health system capacity. In contrast, low performing countries had comprehensive pandemic preparedness plans on paper, caveats and gaps existed with lack of adequate infrastructure to rapidly mobilise and sustain outbreak response measures. Low performing countries also did not take the threat of COVID-19 seriously. Pandemic response plans were devalued at the highest level of government thus denial of scientific evidence led to a failure of leadership to take responsibility or develop comprehensive strategies for infection control. Many of these countries had underfunded public health systems and were unable to take rapid action with delays in launching response mechanisms, making decisions, and changing course based on evolving scientific evidence. Lack of trust of governments seems to fuel the spread of COVID-19 and was a significant undercurrent throughout low performing national responses.

These factors have also been highlighted in a Global Burden of Disease study evaluating COVID-19 data from 177 countries (IHME-GBD, 2022) which found that the level of trust in governments was directly proportional to fewer infections and higher vaccination rates in middle- and high-income countries. Similar messages, and other lessons learnt and recommendations for future pandemic

[☆] Editorial for the IJID 2022 World TB Day special issue

preparedness have also been coming through from other independent political and scientific expert groups and committees from their assessments of the underlying determinants of the COVID-19 pandemic (OECD, 20221; IPPR, 2021; John Hopkins IAE, 2022). Thus these lessons learnt from several COVID-19 innovations in the health systems delivery during lockdowns, and the rapid development and rollout of diagnostics and vaccines highlight the need to stimulate ambitious political and scientific actions for re-vamping global TB control efforts whilst COVID-19 is brought under control (Ntoumi F et al, 2022a; 2022b; Chakaya et al, 2022-IJID; Pai et al, 2022; Ruhwald M et al, 2021, 2022; Hopewell PC et al, 2020; Chapman H et al, 2021; Sahu S et al, 2021; Keene C et al, 2020) Zimmer AJ et al, 2021;. This should also include use of Artificial Intelligence (AI) for improved TB screening at all points of care and rapid data communication (Codlin et al., 2021; Malik et al., 2022). Obtaining accurate data on the actual global burden of LTBI, TB, DRTB, and TB-related deaths is essential to strengthen the evidence base required to convince media, governments and donors to pay specific attention to TB and its continuing status as a global public health emergency. These data gaps should be filled through a universal approach for uniformly collecting more comprehensive, quality and accurate data (Nkengasong et al., 2020), including TB related deaths which remain undiagnosed antemortem, (Mucheleng'anga et al., 2022).

Before the advent of the COVID-19 pandemic the 2018 United Nations High Level Meeting on TB (UNGA-HLM 2018) had brought renewed hope and increased prospects of much-needed global advocacy efforts, political commitment with increased funding required to control TB and achieve the WHO and Stop TB Partnership 'End TB targets' for 2030. To get back UNGA-HLM TB control targets back on track, several activities for enhancing TB case finding utilizing latest available TB diagnostics and treatment regimens (TAG Report, 2021) should be taken forward immediately by national governments in high TB burden countries by aligning TB and COVID-19 services (Ruhwald et al., 2021; USAID, 2021; Ruhwald et al., 2022; Zimmer et al., 2022; Pai et al., 2022; Ntoumi et al., 2022b; Hopewell et al., 2021) Zimmer AJ et al, 2021. Eradication of TB requires increased political will, commitment to providing the required resources, and mutual understanding and respect between politicians, researchers, healthcare workers and communities each recognizing that they all have different but complementary roles. It is imperative that the world now refocuses attention on revamping and reshaping global TB control efforts, and resets the global public health priority agenda to include DR-TB, AMR and COVID-19 altogether. It is also important that TB should be included in the global pandemic preparedness and response agenda, but also in ongoing international dialogue on future pandemic preparedness.

Conflicts of interest:

All authors have an interest in TB and global health. All authors declare no conflicts of interests

Author acknowledgments/declarations:

Authors FN, DY-M and AZ, acknowledge support from Pan-African Network on Emerging and Re-Emerging Infections (PANDORA-ID-NET - <https://www.pandora-id.net/>), CANTAM-3 and EACCR-3 funded by the European and Developing Countries Clinical Trials Partnership the EU Horizon 2020 Framework Programme. Sir Zumla is in receipt of an UK-NIHR Senior Investigator award. He is also a Mahathir Science Award and EU-EDCTP Pascoal Mocumbi Prize Laureate. DG acknowledge supports from the Italian Ministry of health, Ricerca Corrente Linea 4.

Eskild Petersen*

*Institute for Clinical Medicine, Aarhus University, Denmark;
European Travel Medicine Network, Méditerranée Infection
Foundation, Marseille, France*

Seif Al-Abri

*Directorate General for Disease Surveillance and Control, Ministry of
Health, P.O. Box 393, 100, Muscat, Oman*

Jeremiah Chakaya

*Department of Medicine, Therapeutics, Dermatology and Psychiatry,
Kenyatta University, Nairobi, Kenya and Department of Clinical
Sciences, Liverpool School of Tropical Medicine, Liverpool, United
Kingdom*

Delia Goletti

*Istituto Nazionale per le Malattie Infettive: L. Spallanzani IRCCS
Rome, Italy*

Liubov Parolina

*The National Medical Research Center of Phthisiopulmonology and
Infectious Diseases under the Ministry of Health of the Russian
Federation, Moscow, Russia*

Christian Wejse

*Department of Infectious Diseases, Aarhus University Hospital,
Aarhus, Denmark*

Luchenga Adam Mucheleng'anga

*Ministry of Home Affairs, Office of the State Forensic Pathologist, and
PANDORA-ID-NET Pathogenesis Group, University Teaching Hospital,
Lusaka, Zambia*

Sulien Al Khalili

*Directorate General for Disease Surveillance and Control, Ministry of
Health, Sultanate of Oman*

Dorothy Yeboah-Manu

*Noguchi Memorial Institute for Medical Research, University of
Ghana, Legon, Ghana*

Pascalina Chanda-Kapata

Ministry of Health, Lusaka, Zambia

Mohammad Javad Nasiri

*Department of Microbiology, School of Medicine, Shahid Beheshti
University of Medical Sciences, Tehran, Iran*

Patrick S Lungu

*National TB and Leprosy Programme, Ministry Of Health, Lusaka,
Zambia*

Markus Maeurer

*Champalimaud Centre for the Unknown, Lisbon, Portugal;
Medizinische Klinik, Johannes Gutenberg University Mainz, Germany*

Simon Tiberi

*Blizard Institute, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London, London, United Kingdom*

Francine Ntoumi

*Fondation Congolaise pour la Recherche Médicale (FCRM),
Brazzaville, Republic of Congo; Faculty of Sciences and Technology,
University Marien Ngouabi, Brazzaville, Republic of Congo; University
of Tübingen, Tübingen, Germany*

Giovanni Battista-Migliori

*Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti
Clinici Scientifici Maugeri IRCCS, Tradate, Italy*

Alimuddin Zumla

Division of Infection and Immunity, Center for Clinical Microbiology,
University College London, and NIHR Biomedical Research Centre, UCL
Hospitals NHS Foundation Trust, London, United Kingdom

*Correspondence author:

E-mail addresses: eskind.petersen@gmail.com (E. Petersen),
salabri@gmail.com (S. Al-Abri), chakaya.jm@gmail.com (J.
Chakaya), delia.goletti@inmi.it (D. Goletti),
liubov.parolina@gmail.com (L. Parolina), wejse@ph.au.dk (C.
Wejse), luchengam@gmail.com (L.A. Mucheleng'anga),
sulienkhalili18@gmail.com (S.A. Khalili),
Dyeboah-Manu@noguchi.ug.edu.gh (D. Yeboah-Manu),
pascykapata@gmail.com (P. Chanda-Kapata),
mj.nasiri@hotmail.com (M.J. Nasiri), lungupatrick99@gmail.com
(P.S. Lungu), markus.maeurer@fundacaochampalimaud.pt (M.
Maeurer), s.tiberi@qmul.ac.uk (S. Tiberi), fntoumi@fcrm-congo.com
(F. Ntoumi), giovannibattista.migliori@icsmaugeri.it (G.
Battista-Migliori), a.zumla@ucl.ac.uk (A. Zumla)

References

- Chapman HJ, Veras-Estévez BA. Lessons Learned During the COVID-19 Pandemic to Strengthen TB Infection Control: A Rapid Review. *Glob Health Sci Pract* 2021;9(4):964–77.
- Codlin AJ, Dao TP, Vo LNQ, et al. Independent evaluation of 12 artificial intelligence solutions for the detection of tuberculosis. *Sci Rep* 2021;11:23895 <https://doi.org/10.1038/s41598-021-03265-0>.
- Haldane V, De Foo C, Abdalla SM, et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. *Nat Med* 2021a;27:964–80 <https://doi.org/10.1038/s41591-021-01381-y>.
- Report IPPPR. COVID-19: Make it the Last Pandemic by The Independent Panel for Pandemic Preparedness & Response https://theindependentpanel.org/wp-content/uploads/2021/05/COVID-19-Make-it-the-Last-Pandemic_final.pdf.
- Ruhwald M, Carmona S, Pai M. Learning from COVID-19 to reimagine tuberculosis diagnosis. *Lancet Microbe* 2021;2(5):e169–70. doi:10.1016/S2666-5247(21)00057-4.
- UNGA. United Nations General Assembly Resolution A/RES/73/3 Political Declaration of the High-Level Meeting of the General Assembly on the fight against tuberculosis.2018 https://www.un.org/en/ga/search/view_doc.asp?symbol=A/RES/73/3.
- Wu Z, Chen J, Xia Z, Pan Q, Yuan Z, Zhang W, et al. Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China. *Int J Tuberc Lung Dis* 2020;24:1122–4 <https://doi.org/10.5588/ijtld.20.0539>.
- Zumla A, Chakaya J, Khan M, Fatima R, Wejse C, Al-Abri S, et al. World Tuberculosis Day 2021 Theme - 'The Clock is Ticking' - and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. *Int J Infect Dis* 2021;Dec;113 Suppl 1::S1–6. doi:10.1016/j.ijid.2021.03.046.
- Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 Pandemic on Tuberculosis Control: An Overview. *Trop Med Infect Dis*. 2020 Jul 24;5(3):123. doi:10.3390/tropicalmed5030123. PMID: 32722014; PMCID: PMC7558533.
- WHO. 2021a. Global tuberculosis report 2021. October 14, 2021 <https://www.who.int/publications/i/item/9789240037021> -accessed 21.01.2022
- WHO. 2022b. World Health Organization Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/> -Accessed 17th February, 2022
- WHO. 2022a. World TB Day 2022. [https://www.who.int/campaigns/world-tb-day/2022-file:///C:/Users/Prof%20Zumla/Downloads/simultaneous_testing_tb_covid%20\(3\).pdf](https://www.who.int/campaigns/world-tb-day/2022-file:///C:/Users/Prof%20Zumla/Downloads/simultaneous_testing_tb_covid%20(3).pdf) accessed 17th February, 2022
- USAID and STOPTBP. 2021: Implementation of simultaneous diagnostic testing for COVID-19 and TB in high TB burden countries. <https://www.stoptb.org/news/practical-guide-to-implement-simultaneous-testing-tb-and-covid-19> =accessed 18th February, 2022
- TAG. 2021 Pipeline Report – Tuberculosis diagnostics, Tuberculosis Preventive treatment, Tuberculosis treatment, Tuberculosis vaccines <https://www.treatmentactiongroup.org/resources/pipeline-report/2021-pipeline-report/> -accessed 21.01.2022
- Sahu S, Ditiu L, Sachdeva KS, Zumla A. Recovering from the Impact of the Covid-19 Pandemic and Accelerating to Achieving the United Nations General Assembly Tuberculosis Targets. *Int J Infect Dis*. 2021 Dec;113 Suppl 1:S100–S103. doi: 10.1016/j.ijid.2021.02.078. Epub 2021 Mar 11. PMID: 33716198; PMCID: PMC7948527.
- Ruhwald M, Hannay E, Sarin S, Kao K, Sen R, Chadha S. Considerations for simultaneous testing of COVID-19 and tuberculosis in high-burden countries. *Lancet Glob Health*. 2022 Feb 2:S2214–109X(22)00002–X. doi: 10.1016/S2214-109X(22)00002-X. Epub ahead of print. PMID: 35122718; PMCID: PMC8809899.
- Zimmer AJ, Klinton JS, Oga-Omenka C, Heitkamp P, Nawina Nyirenda C, Furin J, Pai M. Tuberculosis in times of COVID-19. *J Epidemiol Community Health*. 2022 Mar;76(3):310–316. doi: 10.1136/jech-2021-217529. Epub 2021 Sep 17. PMID: 34535539; PMCID: PMC8453591
- Pai M, Kasaeva T, Swaminathan S. Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery. *N Engl J Med*. 2022 Jan 5. doi: 10.1056/NEJMp2118145. Epub ahead of print. PMID: 34986295
- OECD. 2022, Trust in government. www.oecd.org/gov/trust-in-government.htm -accessed 10 Feb 2022. OECD. First lessons from government evaluations of covid-19 responses: a synthesis. www.oecd.org/coronavirus/policy-responses/first-lessons-from-government-evaluations-of-covid-19-responses-a-synthesis-483507d6. -accessed 10th February, 2022
- Ntoumi F, Nachega J, Akilillu E, Chankaya J, Felker J, et al. Aligning COVID-19 and TB innovations to save lives and End TB. *Lancet Infect Dis*. 2022b, -in press.
- Ntoumi F, Zumla A. Progress towards defining contextual factors related to COVID-19 infection and mortality rates for future pandemic preparedness. *Lancet* 2022a -in press
- Chakaya J, Petersen E, Nantanda R, Mungai B, Migliori GB, Amanullah F, et al. The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to EndTB. *Int J Infect Dis*. 2022, under review.
- Hopewell PC, Reichman LB, Castro KG. Parallels and Mutual Lessons in Tuberculosis and COVID-19 Transmission, Prevention, and Control. *Emerg Infect Dis*. 2021 Mar;27(3):681–686. doi: 10.3201/eid2703.203456. Epub 2020 Nov 19. PMID: 33213689; PMCID: PMC7920655.
- IHME-GBD. 2022, COVID-19 National Preparedness Collaborators. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. *Lancet*. :S0140-6736(22)00172-6. doi: 10.1016/S0140-6736(22)00172-6. Epub ahead of print. PMID: 35120592.
- John Hopkins Report 2022: Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise. Lockdowns on COVID-19 Mortality, Studies in Applied Economics 200, SAE./No.200/January 2022. <https://ideas.repec.org/p/ris/jhisae/0200.html> -accessed 10th February, 2022
- Keene C, Mohr-Holland E, Cassidy T, Scott V, Nelson A, Furin J, et al. How COVID-19 could benefit tuberculosis and HIV services in South Africa. *Lancet Respir Med*. 2020; 8: 844–846 [https://doi.org/10.1016/S2213-2600\(20\)30311-8](https://doi.org/10.1016/S2213-2600(20)30311-8)
- Malik AA, Hussain H, Maniar R, Safdar N, Mohiuddin A, Riaz N, et al. Integrated Tuberculosis and COVID-19 Activities in Karachi and Tuberculosis Case Notifications. *Trop Med Infect Dis*. 2022 Jan 15;7(1):12. doi:10.3390/tropicalmed7010012. PMID: 35051128.
- Mucheleng'anga, LA, Himazwe CM, Telendiy V, Simumba S, Soko J, Kayonde N, et al. Incidental Tuberculosis in sudden, unexpected, or violent deaths in the community Lusaka, Zambia - A descriptive forensic post-mortem examination study. *Int J Infect Dis*. 2022, WTBDay Issue -under review
- Nkengasong J, Gudo E, Macicame I, Maunze X, Amouzou A, Banke K, et al. Improving birth and death data for African decision making. *Lancet Glob Health*. 2020 Jan;8(1):e35–e36. doi: 10.1016/S2214-109X(19)30397-3. PMID: 31839138.